Vistagen Therapeutics reported fiscal year 2027 first quarter results ending June 30, 2026. The company recognized $1.48 million in revenue due to the expiration of an exclusivity period under its agreement with Fuji Pharma. Operating expenses totaled $14.8 million, comprising $10.9 million in research and development costs and $3.9 million in general and administrative expenses, resulting in a net loss of $13.0 million compared to $15.1 million in the prior year period. Cash, cash equivalents, and marketable securities stood at $31.7 million as of June 30, 2026. Clinically, Vistagen announced preliminary data from the open-label extension of PALISADE-3 for fasedienol and post-hoc data from Phase 3 study PALISADE-4 showing nominally statistically significant improvement in a subpopulation with very severe social anxiety disorder. The company plans to engage with the FDA regarding the future Phase 3 path for fasedienol and received an FDA 'Study May Proceed' letter for refisolone. Additionally, Vistagen appointed Angel S. Angelov as Chief Medical Officer and Douglas J. Williamson to its Board of Directors. Vistagen Therapeutics is a late clinical-stage biopharmaceutical company developing rapid-onset intranasal product candidates called pherines.

Vistagen Therapeutics announced topline results from an exploratory Phase 2 repeat dose study of fasedienol nasal spray for social anxiety disorder on August 6, 2026. The three-arm trial (N=61) met safety objectives and showed numerical separation from placebo in the primary endpoint, with nominally statistically significant improvements in patients with very severe social anxiety (LSAS ≥95). Responder rates were directionally higher for fasedienol across secondary endpoints. These findings support upcoming discussions with the FDA regarding a potential registrational pathway for fasedienol. Vistagen Therapeutics is a late clinical-stage biopharmaceutical company developing intranasal neurocircuitry-focused product candidates.

Vistagen Therapeutics received a 180-day extension from Nasdaq until February 1, 2027, to regain compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company has not yet regained compliance and intends to cure the deficiency within this period; failure to do so may result in delisting proceedings. Vistagen Therapeutics operates in the biotechnology industry, focusing on drug discovery and development.

Vistagen Therapeutics appointed Douglas J. Williamson, M.D., as a director effective July 29, 2026. Dr. Williamson received stock options to purchase up to 40,826 shares at an exercise price of $0.2433 per share under the Company’s Director Compensation Plan. The options vest in equal annual installments over three years and have a ten-year term. Vistagen Therapeutics is a late clinical-stage biopharmaceutical company developing intranasal neuroscience product candidates.

On June 30, 2026, Vistagen Therapeutics announced that its PALISADE-4 Phase 3 trial of intranasal fasedienol for acute social anxiety disorder failed to meet its primary endpoint. The least squares mean change from baseline on the Subjective Units of Distress Scale (SUDS) was -9.5 for fasedienol versus -11.4 for placebo (p=0.427), and no treatment difference was found for secondary endpoints. However, a post-hoc analysis of a subpopulation with very severe social anxiety (LSAS score ≥ 95) showed nominal statistical significance (p=0.036). The company plans to pivot its regulatory strategy toward a potential registrational pathway focused on the overall treatment of social anxiety disorder and believes cash resources will support operations into 2027. Vistagen is a biopharmaceutical company developing pherine product candidates for CNS disorders.